GrittGene Therapeutics
GrittGene Therapeutics is dedicated to developing innovative treatments for genetic diseases, particularly Myotonic Dystrophy Type 2, by employing cutting-edge technologies including CRISPR and Artificial Intelligence. The company aims to find a cure rather than just cover symptoms, utilizing a disease-centric, interdisciplinary platform free from the constraints of big pharma. Their approach involves tissue-specific delivery, gene-specific editing, and collaboration across sectors to accelerate the development of cures.
Industries
Nr. of Employees
small (1-50)
GrittGene Therapeutics
Glendale, California, United States, North America
Products
Guide RNA candidate database (development)
Planned or in-development guide RNA database to support selection and screening of CRISPR guide sequences.
Guide RNA candidate database (development)
Planned or in-development guide RNA database to support selection and screening of CRISPR guide sequences.
Services
Viral vector production and process development (research-grade)
Research-grade production and process characterization for viral vectors including upstream and downstream workflows, process optimization, and SOP documentation.
Diagnostics and laboratory support for clinical trials
Laboratory diagnostic services to support clinical trials across America, Europe and Asia.
Assay development and sequencing-based analytical services
Design and execution of cell-based assays, high-throughput screening assays and sequencing assays to assess genetic editing outcomes.
Viral vector production and process development (research-grade)
Research-grade production and process characterization for viral vectors including upstream and downstream workflows, process optimization, and SOP documentation.
Diagnostics and laboratory support for clinical trials
Laboratory diagnostic services to support clinical trials across America, Europe and Asia.
Assay development and sequencing-based analytical services
Design and execution of cell-based assays, high-throughput screening assays and sequencing assays to assess genetic editing outcomes.
Expertise Areas
- CRISPR gene editing and gene therapy development
- Viral vector design and biomanufacturing (AAV, lentivirus)
- RNA therapeutics and siRNA delivery
- Preclinical in vitro and in vivo model development
Key Technologies
- CRISPR-Cas9 gene editing
- Adeno-associated virus (AAV) vectors
- Lentiviral vectors
- Next-generation sequencing (NGS)